Document ID: chunk:federal_register_of_legislation:F2024L00755:reg:9:p2
Version: federal_register_of_legislation:F2024L00755
Segment Type: reg
Provision Reference: reg 9 (pt 2/2)
Character Range: 7165–9145

dislodged, cut or drilled; and
(c)          where the first inhalation of respirable asbestos fibres commenced at least five years before the clinical onset of malignant neoplasm of the intrahepatic bile duct;
Note: hazardous asbestos fibres (chrysotile (white asbestos),  amosite (brown asbestos), crocidolite (blue asbestos)) are an asbestos fibre less than 3 micrometres in diameter and at least 5 micrometres long (with a width to length ratio of greater than 1:3).
(13)      undergoing solid organ transplantation excluding corneal transplant, at least 5 years before clinical onset;
(14)      smoking at least 30  pack-years of cigarettes, or the equivalent thereof in other tobacco products, before clinical onset, and:
(a)          smoking commenced at least 5 years before the clinical onset of malignant neoplasm of the bile duct; or
(b)          where smoking has ceased, the clinical onset of malignant neoplasm of the bile duct has occurred within 20 years of cessation;
Note: one pack-year is defined in the Schedule 1 - Dictionary.
(15)      having non-alcoholic fatty liver disease for at least 5 years within the 20 years before clinical onset;
(16)      consuming at least 400 kilograms of alcohol at least 5 years before clinical onset;
(17)      inhaling, ingesting or having cutaneous contact with 1,2-dichoropropane for at least 1,000 ppm-years at least 2 years before clinical onset;
Note: ppm-years is defined in the Schedule 1 – Dictionary.
(18)      having an infection with Helicobacter pylori, Helicobacter bilis or Helicobacter hepaticus at least 10 years before clinical onset;
(19)      having IgG4 sclerosing cholangitis before the clinical onset of malignant neoplasm of the bile duct;
(20)      having evidence of infection with Epstein-Barr virus before the clinical onset of lymphoepithelioma-like bile duct cancer;
(21)      inability to obtain appropriate clinical management for malignant neoplasm of the bile duct before clinical worsening.